Yevgeniy Brailovsky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yevgeniy Brailovsky has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Sadek
CTEPH Program, Department of Medicine, Division of Cardiology, Pulmonary Hypertension, Right Heart Failure, Temple University Hospital, Philadelphia, PA 19140, USA
1 shared publication - Anil Kumar Jonnalagadda
CTEPH Program, Department of Medicine, Division of Cardiology, Pulmonary Hypertension, Right Heart Failure, Temple University Hospital, Philadelphia, PA 19140, USA
1 shared publication - Anjali Vaidya
Division of Cardiovascular Disease, Department of Medicine, Temple University Hospital, Philadelphia, PA 19140, USA
1 shared publication - Estefania Oliveros
Columbia University Department of Medicine
1 shared publication - Hollie Saunders
CTEPH Program, Department of Medicine, Division of Cardiology, Pulmonary Hypertension, Right Heart Failure, Temple University Hospital, Philadelphia, PA 19140, USA
1 shared publication - Huaqing Zhao
Department of Biomedical Education and Data Science, Center for Biostatistics and Epidemiology, Lewi Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA
1 shared publication
Latest Publications
- Open Access
- 12 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (16) , 5705
Echo-Doppler Predictors of Residual Pulmonary Hypertension After Pulmonary Thromboendarterectomy
Background: Pulmonary thromboendarterectomy (PTE) remains the preferred treatment for surgical accessible thrombus in patients with chronic thromboembolic pulmonary hypertension (CTEPH). However, residual pulmonary hypertension (PH) can persist post-PTE. Methods: A retrospective single-center analysis of patients that underwent PTE between 2013 and 2023. At 3-month follow-up, we performed a qualitative Echo-Doppler (DE) assessment and applied a semi-quantitative DE scoring system (DESS), assigning point values for six DE parameters: right ventricle (RV) size, RV shape (systolic base–apex ratio), RV function, septal position, tricuspid regurgitation (TR) and RV outflow tract notching (RVOTN). Higher scores suggested a more significant residual PH syndrome. Results: A total of 188 subjects (80%) did not require further PH intervention at ≥3 months (Group A); 48 (20%) required ongoing PH treatment (Group B). The pre-PTE median DESS was 10 and the post-PTE median DESS was 3.00 (range 0–16). The maximum DESS was 17. Using ROC analysis, post-PTE DESS strongly discriminated between Group A and B (AUC 0.76; 95% CI 0.65–0.89; p < 0.001). A post-PTE DESS of >6.5 differentiated Group A and B. Evidence of TR (OR 0.191, CI 0.103–0.279; p < 0.0001) and RV enlargement (OR 0.242; CI 0.153–0.330; p < 0.0001) at follow-up was associated with a need for additional PH interventions. Conclusions: Serial DE examination is a viable, noninvasive method to assess significant residual PH post-PTE.
- 12 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (16) , 5705
Open AccessEcho-Doppler Predictors of Residual Pulmonary Hypertension After Pulmonary Thromboendarterectomy
Background: Pulmonary thromboendarterectomy (PTE) remains the preferred treatment for surgical accessible thrombus in patients with chronic thromboembolic pulmonary hypertension (CTEPH). However, residual pulmonary hypertension (PH) can persist post-PTE. Methods: A retrospective single-center analysis of patients that underwent PTE between 2013 and 2023. At 3-month follow-up, we performed a qualitative Echo-Doppler (DE) assessment and applied a semi-quantitative DE scoring system (DESS), assigning point values for six DE parameters: right ventricle (RV) size, RV shape (systolic base–apex ratio), RV function, septal position, tricuspid regurgitation (TR) and RV outflow tract notching (RVOTN). Higher scores suggested a more significant residual PH syndrome. Results: A total of 188 subjects (80%) did not require further PH intervention at ≥3 months (Group A); 48 (20%) required ongoing PH treatment (Group B). The pre-PTE median DESS was 10 and the post-PTE median DESS was 3.00 (range 0–16). The maximum DESS was 17. Using ROC analysis, post-PTE DESS strongly discriminated between Group A and B (AUC 0.76; 95% CI 0.65–0.89; p < 0.001). A post-PTE DESS of >6.5 differentiated Group A and B. Evidence of TR (OR 0.191, CI 0.103–0.279; p < 0.0001) and RV enlargement (OR 0.242; CI 0.153–0.330; p < 0.0001) at follow-up was associated with a need for additional PH interventions. Conclusions: Serial DE examination is a viable, noninvasive method to assess significant residual PH post-PTE.